An Additional Confirmatory Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD)

Phase 3

Completed

• Conditions: Spinocerebellar Degeneration
• Interventions: Drug: Placebo; Drug: KPS-0373

• Registration Number: NCT02889302
• Lead Sponsor: Kissei Pharmaceutical Co., Ltd.

Brief Summary

The purpose of this study is to investigate the superiority of KPS-0373 to placebo, and evaluate the safety of KPS-0373 in SCD patients.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2016-08-31
• Study First Submitted QC: 2016-08-31
• Study First Posted: 2016-09-05
• Study Start: 2016-11-15
• Primary Completion: 2018-03
• Study Completion: 2018-03
• Status Verified: 2018-12
• Last Update Submitted: 2018-12-12
• Last Update Posted: 2018-12-14

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 203

Inclusion Criteria

• Japanese SCD patients with mild to moderate ataxia

Read More

Exclusion Criteria

• Patients with secondary ataxia
• Patients with clinically significant hepatic, renal, or cardiovascular dysfunction

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Placebo	Placebo	-
KPS-0373	KPS-0373	-

Primary Outcome Measures

Name	Time	Method
SARA (Scale for the Assessment and Rating of Ataxia)	24 weeks	The change in the SARA total score at the time of final evaluation

Secondary Outcome Measures

Name	Time	Method
SF-8(QOL)	24 weeks